Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice

Naoki Arai, Mitsuko Kondo, Takehiro Izumo, Jun Tamaoki, Atsushi Nagai
First Department of Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo 162-8666, Japan

Address correspondence to Mitsuko Kondo, M.D., First Department of Medicine, Tokyo Women’s Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku, Tokyo 162-8666, Japan
(Phone: 81-3-3353-8111; Fax: 81-3-5379-5457; e-mail: mikondo@chi.twmu.ac.jp)

Short title: INHIBITION OF MUCUS BY TIOTROPIUM (33 characters)

Word count of the article: 3657
Abstract

Airway occlusion by mucus in COPD is associated with a poor prognosis. We hypothesized that tiotropium has the ability to inhibit neutrophil elastase (NE)–induced goblet cell metaplasia in mice and mucin production in vitro.

On Days 1, 4, and 7, tiotropium or vehicle was administered to C57BL/6 mice by inhalation, and they were allowed to intranasally aspirate human NE. Bronchoalveolar lavage fluid (BALF) and lung sections were analyzed on Days 8, 11, and 14. The effect of late administration of tiotropium on the goblet cell metaplasia by NE aspiration was also assessed. NE-induced MUC5AC production by NCI-H292 cells was measured with ELISA.

Repeated-NE aspiration induced marked goblet cell metaplasia. The grading of goblet cell metaplasia, neutrophil count and eosinophil count in BALF, KC level and leukotriene B4 level in BALF, M3 receptor expression by immunohistochemistry were lower in the tiotropium group than in the vehicle group. Late administration of tiotropium inhibited the established goblet cell metaplasia. Tiotropium inhibited NE-induced MUC5AC production.

Tiotropium inhibited NE-induced goblet cell metaplasia and mucin production, probably mediated by suppression of inflammation and a direct action on epithelial cells. This result suggests that tiotropium may be useful for the treatment of mucus overproduction in COPD. (200 words)

Key words

Goblet cell metaplasia, inflammation, mucin, neutrophil elastase, tiotropium
Introduction

Mucus overproduction due to goblet cell metaplasia is one of the characteristic features of chronic obstructive pulmonary disease (COPD). It has recently been reported that occlusion of bronchial lumens by mucus containing inflammatory exudates is negatively correlated with FEV$_{1.0}$ over the full range of COPD severity [1]. Reduction of FEV$_{1.0}$ leads to more frequent exacerbations of COPD. Impaired mucus clearance is associated with pneumonia that results in early death in patients with severe COPD [2]. Thus, mucus control may serve as a therapeutic target for improving the prognosis of COPD.

Neutrophil elastase (NE) is a serine protease that stimulates mucus secretion [3], and its level is increased in the sputum with nanomolar or micromolar concentrations in chronic bronchitis [4]. NE is generally used for an animal model of emphysema based on the hypothesis that COPD is caused by an imbalance between protease activity and antiprotease activity. Although the studies were focused on assessing the destruction of alveoli and small airways, goblet cell metaplasia has not fully been studied in this model.

The long-acting cholinergic antagonist tiotropium is widely used as a bronchodilator in the treatment of COPD. Because tiotropium improves FEV$_{1.0}$ and the SGRQ score, increases the time to the first exacerbations, and reduces the number of exacerbation of COPD [5, 6]. There is accumulating evidence that the cholinergic system not only controls contraction by airway smooth muscle but also the functions of inflammatory cells and airway epithelial cells [7]. Recent evidence suggests that tiotropium has anti-inflammatory effect in COPD. In this study we investigated whether tiotropium has the ability to inhibit goblet cell metaplasia in a NE-induced murine model of COPD. In addition, we investigated whether tiotropium directly inhibits NE-induced mucin production in NCI-H292, a well-established cell line to study mucin production [8].
Materials and Methods

**In vivo study using a NE-induced murine model of COPD**

The animal protocol was approved by the Animal Care and Use Committee of Tokyo Women’s Medical University. We used 6-week-old C57BL/6 male mice, and divided them into two groups. The first protocol (protocol A) is shown as Figure 1A. On Days 1, 4, and 7, tiotropium or vehicle was administered by inhalation to the groups for 30 min by placing 5-10 mice per group in an acrylic box (14.5 x 21.0 x 14.5 cm) under conscious and unrestrained condition and exposing them to aerosols of tiotropium diluted in sterile saline (10^{-5} \text{ M}, Boehringer Ingelheim Co., Germany) or vehicle (sterile saline) with an ultrasonic nebulizer (Pulmo-Sonic model 25, De Vilbiss Co. PA). The aerosols were allowed to escape through two exhaust holes (1 cm) on the side panels of the box to ensure constant airflow. 30 min after the completion of the inhalation, both groups were allowed to intranasally aspirate human NE (50 \mu g, Elastin Products, Owensville, MO) dissolved in saline 80 \mu l under ether anesthesia. The group exposed to tiotropium will be referred to as the tiotropium group, and the group exposed to vehicle will be referred to as the NE group. Bronchoalveolar lavage fluid (BALF) and the histology of the lung tissues were analyzed on Day 8, 11, and 14. The NE group and the tiotropium group on each day will be referred to as N8, N11, and N14 and as T8, T11, and T14, respectively. Since we confirmed that mice that aspirated saline intranasally on Days 1, 4, and 7 developed little or no goblet cell metaplasia, the same as reported by Voynow JA [9], we used mice that had aspirated NE in this study to elucidate the effect of tiotropium. To assess the time course of goblet cell metaplasia, the NE group on Day 20 (N20) and non-treated control mice group were analyzed for histology of the lung tissues as a separate experiment.

For BALF analysis, mice were anesthetized with pentobarbital (50 mg/kg, ip), and after performing a tracheotomy, a custom-built cannula was inserted into the trachea. The lungs
were lavaged with 1.0 ml of saline or PBS, and then with 0.8 ml of the same solution. The BALF was centrifuged at 360 g for 10 min, and the supernatant was collected and stored at -80°C for subsequent measurement of keratinocyte-derived chemokine (KC); the mouse ortholog of human IL-8, IL-5, and leukotriene B4 (LTB4). The total cell was counted manually with a hemocytometer. Slides of BALF cells were prepared with cytopsin, and after staining with May-Grünwald-Giemsa stain, differential counts of ~1000 cells per sample were made. The KC levels and IL-5 levels in BALF were measured with a mouse KC and IL-5 ELISA kit (R&D system, Minneapolis, MN). The LTB4 levels in BALF were measured with an enzyme immunoassay system (Amersham Biosciences, Piscataway, NJ).

For histological analysis of the lungs, the lungs were fixed by inflation with 4% paraformaldehyde and embedded in paraffin. Sections were cut 5 µm thick and stained with PAS/Alcian-blue. The assessments were made at stratified random fields (n = 5) in each animal, as described by Nagai A. et al [10]. Goblet cell metaplasia was assessed in bronchi measuring more than 200 µm in internal diameter in cross section by using a mucus grading system (scores 0-3), based on the ratio of goblet cell area to whole cross-sectional epithelial area in each round bronchus. A score of 0; none, score 1; occupied < 1/3 of the epithelial area, score 2; occupied ≥ 1/3 - < 2/3 of the epithelial area, score 3; occupied ≥ 2/3 of the epithelial area. The mucus score was obtained by averaging the scores of measured bronchi.

For immunohistochemistry, after deparaffinizing in sections xylene and dehydrating in them ethanol, they were reacted with peroxidase-blocking solution (DakoCytomation, A/S, Denmark) for 10 minutes at room temperature to block endogenous peroxidase activity. Next, they were reacted with Protein Block Serum-Free (DakoCytomation) for 10 minutes at room temperature. The sections were then incubated with goat polyclonal anti-M3 antibody (1:100, C-20, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at room temperature for 1h. The primary antibodies were then reacted with the labeled polymer prepared by combining amino
acid polymers with peroxidase and secondary antibody (N-Histofine Simple Stain Mouse MAX PO, Nichirei Bioscience, Tokyo, Japan). Immunoreactants were visualized with 3,3′-diaminobenzidine (DAB) and counterstained with nuclear fast red solution. For negative controls, tissue sections were incubated without the addition of primary antibody.

In the second protocol (protocol B, Figure 1B), which was designed to assess the therapeutic effect of late administration of tiotropium on established goblet cell metaplasia in the NE-induced COPD model, the mice were allowed to intranasally aspirate NE six times, i.e., on Days 1, 4, 7, 10, 13, and 16. Late tiotropium or vehicle treatment was administered on Days 10, 13, and 16, by allowing animals to inhale tiotropium (10⁻⁵ M) for 30 min before the NE aspiration on these days. On Day 20, BALF was analyzed and the goblet cell metaplasia of the lung tissue was assessed by the same methods as above. The NE group and the tiotropium group on Day 20 in the experiment of late administration will be referred to as L-N20 and L-T20, respectively.

**In vitro study using NCI-H292 cells**

**Cell culture**

Human pulmonary mucoepidermoid carcinoma cell line NCI-H292 was grown at 37° C in RPMI 1640 medium (GIBCO) with 10% FCS, penicillin (100 U/ml), streptomycin (100 µg/ml), and fungizone (2.5 µg/ml) in a humidified 5% CO₂ water-jacketed incubator. NCI-H292 cells were plated in 6 well culture dishes at an initial density of 1x10⁵/well and reached confluence 5 days after plating. The cells 2 days after confluence were used for *in vitro* experiment. The cell density of the cells was ~ 4.5 x10⁵/cm².

*Measurement of MUC5AC production*
NCI-H292 cells were serum starved for 24 h by culturing in the same medium without serum. The serum-starved cells were pretreated with tiotropium (10^{-6} - 10^{-5} M) or saline for 30 min, and after replacing the medium with serum-free medium and stimulating them with NE (10^{-7} M) for 10 min [11]. Then, the cells were washed and cultured in serum-free medium for an additional 24 h. MUC5AC protein levels in cell lysates were measured by ELISA (Mucin 5AC mouse monoclonal IgG, Santa Cruz Biotechnology Inc., CA, USA) as previously described by Takeyama K. et al [12]. The data were shown as percent increase over the level in non-stimulated control cells on the same experimental day, but not shown by using a mucin standard curve to calculate MUC5AC protein [13, 14]. In additional experiments, we examined whether ipratropium inhibits NE-induced MUC5AC production, and whether carbachol affects MUC5AC production to confirm the role of muscarinic receptors in NCI-H292 cells. For ipratropium experiment, the cells were pretreated with ipratropium (10^{-5} M, Sigma-Aldrich, St Louis, MO, USA) for 30 min, and stimulated with NE (10^{-7} M) for 10 min. For carbachol experiment, the cells were pretreated with tiotropium (10^{-5} M) or saline for 30 min, and stimulated with carbachol (10^{-6} M, Sigma-Aldrich) for 10 min.

Statistics

Data are expressed as means ± SEM. Multiple comparisons were performed by using the Tukey-Kramer test. Comparisons between two groups were performed by using the two-tailed unpaired Student’s t-test. A P value less than 0.05 was considered significant.

Results

In vivo study

Goblet cell metaplasia
As shown in Figure 2A, NE aspiration three times had induced goblet cell metaplasia with inflammatory cell infiltration when C57BL/6 mice were examined on Day 11, whereas tiotropium pretreatment strongly inhibited the development of goblet cell metaplasia. The mucus score as a measure of NE-induced goblet cell metaplasia was significantly lower in T11 than in N11 (N11 vs. T11: 0.871 ± 0.170 vs. 0.365 ± 0.064; N11, n = 6; T11, n = 7; p < 0.05; Figure 2B). The mucus score in T8 also tended to be lower than that in N8. However, the mucus score in T14 was not different from that in N14. Since the mucus score in N14 was significantly lower than that in N11 (N11 vs. N14: 0.871 ± 0.170 vs. 0.342 ± 0.080, N11, n = 6; N14, n = 5; p < 0.05; Figure 2B), these data indicated that NE-induced goblet cell metaplasia spontaneously reverted at 7 days after last NE exposure. To confirm the reversion, we analyzed the mucus scores in N20 and in non-treated control group as an additional experiment. The mucus score in N20 (0.146 ± 0.270, n = 6) was further decreased as compared with N14 (Figure 2B). However, a slight goblet cell metaplasia remained in N20, whereas non-treated control group had no goblet cell metaplasia.

**BALF analysis**

The total cell count in BALF on Day 11 was significantly lower in the tiotropium group than in the NE group (N11 vs. T11: 19.89 ± 3.02 x 10^4 vs. 10.97 ± 1.10 x 10^4 /ml; p < 0.05; N11, n = 8; T11, n = 9; Figure 3A). Neutrophils were first noted in the NE group on Day 8, and tiotropium inhibited NE-induced neutrophil accumulation on Day 8 (N8 vs. T8: 1.02 ± 0.14 x 10^4 vs. 0.10 ± 0.06 x 10^4 /ml; p < 0.001; N8, n = 9; T8, n = 5; Figure 3C). The eosinophil count on Day 11 was significantly lower in the tiotropium group than in the NE group (N11 vs. T11: 2.55 ± 0.70 x 10^4 vs. 0.68 ± 0.13 x 10^4 /ml; p < 0.05; N11, n = 8; T11, n = 9; Figure 3D). The macrophage counts tended to be lower in the tiotropium group, but the differences were not significant (Figure 3B). There were not significant differences between the lymphocyte counts in the two
groups (data not shown). KC was detected in BALF only on Day 8 (Figure 4A). The KC levels were significantly lower in T8 than in N8 (N8 vs. T8: 10.58 ± 0.75 pg/ml vs. 3.93 ± 0.81 pg/ml; p < 0.001; N8, n = 6; T8, n = 7). IL-5 was detected in BALF on Days 8, 11, and 14 in both groups, but there were no significant differences between the groups (Figure 4B). LTB₄ were detected on Days 8, 11, and 14 in both groups, and the LTB₄ level was significantly lower in the tiotropium group on Day 11 (N11 vs. T11: 151.1±15.7 pg/ml vs. 109.8±11.2 pg/ml; p < 0.05; n = 9; Figure 4C).

Immunohistochemistry

Figure 5 shows M₃ receptor expression of the lung sections by immunohistochemistry on Day 11. Strong M₃ expression was especially observed in bronchial epithelial cells and inflammatory cells in the NE group (Figure 5a). The M₃ receptor expression in the tiotropium group was less than that in the NE group (Figure 5b).

Therapeutic effect of late administration of tiotropium on established goblet cell metaplasia

The results of protocol B showed that tiotropium reversed the established goblet cell metaplasia. Thus, the mucus score as a measure of NE-induced goblet cell metaplasia was significantly lower in L-T20 than in L-N20 (L-N20 vs. L-T20: 0.706 ± 0.062 vs. 0.496 ± 0.078; L-N20, n=12; L-T20, n = 10; p < 0.05; Figure 6A). The total cell count and eosinophil count in BALF were significantly lower in L-T20 than in L-N20 (L-N20 vs. L-T20: total cell count 28.8 ± 6.20 x 10⁴ vs. 13.1 ± 1.57 x 10⁴ /ml; p < 0.05, Figure 6B; eosinophil count 21.4 ± 4.93 x 10⁴ vs. 6.57 ± 1.49 x 10⁴ /ml; p < 0.05; L-N20, n = 12; L-T20, n = 10, Figure 6D). There were no significant differences between the two groups in macrophage count (Figure 6C) or counts of other cells on Day 20 (data not shown).
In vitro study

MUC5AC production in NCI-H292 cells

Figure 7 shows the results of MUC5AC production in NCI-H292 cells. NE increased the MUC5AC level in the NCI-H292 cells in comparison with the control cells, and the percentage of MUC5AC level in NE-treated cells above the level in the control cells was 32.24% ± 8.79% (n = 10, p < 0.05). Tiotropium inhibited NE-induced increase in MUC5AC level (tiotropium 10^{-6} M, 3.66 ± 9.66%; 10^{-5} M, 0.44 ± 4.11%; n = 6; p = 0.054 at 10^{-6} M, p < 0.05 at 10^{-5} M), but tiotropium (10^{-5} M) per se had no effect on baseline MUC5AC production (-1.47 ± 6.02%, n = 9). Ipratropium (10^{-5} M) inhibited NE-induced increase in MUC5AC level (-7.89 ± 1.73%; n = 4, p < 0.05). Carbachol (10^{-6} M) increased the MUC5AC level in NCI-H292 cells (17.14 ± 2.25%, n = 8, p < 0.05), and tiotropium (10^{-5} M) significantly inhibited the carbachol-induced increase in MUC5AC level (1.24 ± 6.55%, n = 7, p < 0.05).

Discussion

In this study we showed that repeated NE aspiration induced marked goblet cell metaplasia in mice in vivo and that its induction was inhibited by tiotropium. A therapeutic effect of tiotropium was also observed on the established goblet cell metaplasia. The results also showed that tiotropium inhibited NE-induced MUC5AC production by NCI-H292 cells in vitro.

We modeled NE-induced goblet cell metaplasia in mice by using a simple technique of intranasal instillation of NE on Days 1, 4, and 7 under ether anesthesia, and the metaplasia was similar to the metaplasia described by Voynow JA et al.[9], who induced it by allowing repeated aspiration of NE via oropharyngeal route. Although the mechanism by which leads to
NE-induced goblet cell metaplasia is not fully elucidated, our data suggest that NE-induced inflammation may be associated with goblet cell metaplasia. Voynow JA et al. reported that NE proteolytic activity is required for goblet cell metaplasia to occur, because the NE inhibitor AAPV-CMK prevented NE-induced goblet cell metaplasia [9].

Our data of protocol A in Figure 1 showed that NE aspiration three times induced marked goblet cell metaplasia in N8 and N11, but spontaneously reverted in N14 and further in N20 (Figure 2B). Therefore, we confirmed that NE-induced goblet cell metaplasia spontaneously reverted at 7 days after last exposure of NE in our mouse model. On the other hand, our data of protocol B showed that NE aspiration six times maintained marked goblet cell metaplasia in L-N20 (Figure 6A). These data suggest that the continuous exposure to NE may be necessary to maintain marked goblet cell metaplasia.

The long-acting muscarinic receptor antagonist tiotropium is widely used as a bronchodilator for the treatment of COPD. In our study tiotropium inhibited the development of NE-induced goblet cell metaplasia, suggesting that remodeling processes, such as NE-induced goblet cell metaplasia are regulated by muscarinic receptors.

Our study also showed that tiotropium reduced the number of inflammatory cells in BALF (Figure 3A), suggesting that tiotropium may have anti-inflammatory action. Furthermore, the lung sections in the tiotropium group showed reduced M₃ receptor expression by immunohistochemistry especially in bronchial epithelial cells and inflammatory cells compared with those in the NE group (Figure 5), suggesting that anti-inflammatory action of tiotropium may have suppressed the NE-induced M₃ receptor expression in our model.

Muscarinic receptors have been known to be located on various cells, including epithelial cells and inflammatory cells. In COPD, macrophages express more M₃ receptors than M₁ or M₂ receptors and the numbers of M₁ and M₃ receptors on neutrophils tend to increase
It was recently reported that tiotropium was found to inhibit the remodeling processes including airway smooth muscle hypertrophy, mucus gland hypertrophy, and goblet cell hyperplasia, as well as inflammation in a guinea pig model of allergic asthma [16]. Although our model may differ from allergic models, a similar mechanism may be involved. Since it is well known that vagal tone is increased by airway inflammation in asthma and COPD, and recent evidence suggests that acetylcholine and its synthesizing enzyme choline-acetyltransferase (ChAT) are ubiquitously expressed throughout the airways, including in epithelial cells and inflammatory cells, and acetylcholine synthesized by the ChAT is involved in the stimulation of postjunctional target cells by non-neuronal mechanism [7, 17], autocrine and paracrine stimulation of muscarinic receptors by acetylcholine secreted or produced through the inflammatory process may cause remodeling, including goblet cell metaplasia.

The results of our study also showed that the goblet cell metaplasia established in our COPD model was inhibited by late administration of tiotropium (protocol B). Tiotropium has been reported to prolong the time to the first exacerbation in a clinical study of COPD. Because excessive mucus secretion is the one of major symptoms in exacerbations of COPD, the therapeutic effect of tiotropium may be associated with inhibition of goblet cell metaplasia.

Our data showed that the increase of neutrophils in BALF on Day 8, and of eosinophils on Day 11 was inhibited by tiotropium (Figure 3C, 3D) and that the increase in KC level in BALF was inhibited by tiotropium (Figure 4A). These findings suggest that tiotropium suppressed neutrophil accumulation by causing a decrease in KC. By contrast, IL-5 was detected on Days 8, 11, and 14, but the increases in IL-5 level were not inhibited by tiotropium. We also measured eotaxin, but difference in the levels between the two groups was not significant (data not shown). The levels of other eosinophilic chemoattractants, i.e., GM-CSF and RANTES, were reported to be below the level of detection in a previous study on
NE-induced model of mice [9], suggesting that Th2-type eosinophilic chemoattractants may not be associated with the inhibitory effect of tiotropium in this model.

Interestingly, our data showed that the LTB4 levels in BALF were increased in the NE-induced COPD model and that on Day 11 the LTB4 level was lower in the tiotropium group than in the NE group (Figure 4C). Because LTB4 contributes to the recruitment and activation of leukocytes, including both eosinophils and neutrophils, by via BLT1[18], the increase in eosinophils in BALF on Day 11 may have been mediated by LTB4. Recent evidence suggests that muscarinic receptors are involved in airway inflammation in COPD patients through ACh-induced, ERK1/2-dependent LTB4 release from sputum cells and monocytes [15]. Since Buhling F. et al found that most neutrophil chemotactic activity released from macrophages, monocytes, and epithelial cells in response to ACh could be attributed to LTB4 [19], tiotropium may interrupt the vicious cycle of inflammation induced by LTB4 production via muscarinic receptors in COPD.

Our *in vitro* study demonstrated that tiotropium inhibited NE-stimulated MUC5AC production (Figure 7), suggesting a direct effect of tiotropium on NE-induced mucin production in airway epithelial cells. NE has been found to act on the epithelial cell surface [20] and activate signaling via multiple pathways, including generation of reactive oxygen species [21, 22], activation of toll-like receptor 4 [23] and activation of the epidermal growth factor receptor (EGFR) [11]. TGF-α cleaved by NE and reactive oxygen species produced by NE have been shown to activate EGFR and induce MUC5AC production in NCI-H292 cells *in vitro* [11]. Our study showed that tiotropium inhibited carbachol-induced increase in MUC5AC production and that another muscarinic receptor antagonist ipratropium inhibited NE-induced increase in MUC5AC, suggesting that effects of NE on mucin production are explained by activation of muscarinic receptors in NCI-H292 cells. As a classical study demonstrated that NE affects muscarinic-receptor-mediated events in airway smooth muscles [24], the interaction between
NE and muscarinic receptors may be involved in mucin production by NCI-H292 cells. Although it may be difficult to apply the results of in vitro experiments using human cell line into in vivo study of mice, we speculate that tiotropium may have inhibited goblet cell metaplasia by inhibiting NE-induced MUC5AC protein production via direct action on epithelial cells in our model. However, further studies are needed to demonstrate the effect of tiotropium on NE-induced goblet cell metaplasia or MUC5AC production by using primary epithelial cells in mice.

Our studies demonstrated that tiotropium inhibits NE-induced goblet cell metaplasia in vivo and mucin production in vitro, probably mediated by suppression of inflammation and by a direct effect on epithelial cells. Since mucus overproduction is associated with a poor prognosis of COPD, tiotropium may be an effective drug for treating mucus overproduction in COPD.

Acknowledgments

The authors thank Masayuki Shino and Yoshimi Sugimura for their technical assistance.
Reference


Figure legends

Figure 1. Experimental protocols

A) Protocol A: On Days 1, 4, and 7, C57BL/6 mice inhaled tiotropium ($10^{-5}$ M) (tiotropium group) or vehicle (NE group) for 30 min, and they aspirated human NE (50 µg) under ether anesthesia intranasally. The mice were sacrificed on Days 8, 11, and 14, and bronchoalveolar lavage fluid (BALF) and the lung sections were examined. The NE group on Days 8, 11, and 14 and the tiotropium group on Days 8, 11, and 14 are referred to as N8, N11, and N14 and as T8, T11, and T14, respectively.

B) Protocol B: Effect of late administration of tiotropium on established NE-induced goblet cell metaplasia. Mice aspirated NE alone intranasally on Days 1, 4, and 7. On Days 10, 13, and 16, mice inhaled tiotropium (tiotropium group) or vehicle (NE group), and then aspirated NE. The mice were sacrificed on Day 20, and BALF and the lung sections were examined. The NE group on Day 20 and the tiotropium group on Day 20 are referred to as L-N20 and L-T20, respectively.
Figure 2. Effect of tiotropium on NE-induced goblet cell metaplasia.

A) Photomicrographs of bronchi from the NE group and tiotropium group on Day 11.

a) NE group: The bronchi of the NE group showed marked goblet cell metaplasia and recruitment of inflammatory cells around the bronchus. b) Tiotropium group: The bronchi of the tiotropium group showed a decrease in goblet cell metaplasia and infiltration by inflammatory cells. PAS/Alcian blue stain. Scale bar; 200 µm.

B) Comparison of mucus scores in the NE group and tiotropium group, and time course of NE-induced goblet cell metaplasia. The mucus score for each specimen was obtained by averaging the scores of bronchi. Tiotropium was found to have inhibited goblet cell metaplasia when examined on Day 11. Goblet cell metaplasia appeared in N8 and N11, but spontaneously reverted in N14 and further in N20. Non-treated control group (Cont) had no goblet cell
metaplasia. Closed bars: NE group. Open bars: Tiotropium group. Data shown are means ± SEM. NE group = 5-7, Tiotropium group = 4-7, Cont group = 6. * p < 0.05, N11 vs. T11. † p < 0.01, N8, N11 vs. Cont, N20. # p < 0.05, N11 vs. N14.
Figure 3. Comparison between the results of the BALF cell analysis in the NE group and tiotropium group. A) total cell count, B) macrophage count, C) neutrophil count, D) eosinophil count. Tiotropium inhibited the increase in the total cell count and eosinophil count on Day 11 and the increase in neutrophil count on Day 8. Closed bars: NE group. Open bars: Tiotropium group. Data shown are means ± SEM. n = 5-9. † p < 0.001, N8 vs. N11 or N14. * p < 0.05, N11 vs. T11. ** p < 0.001, N8 vs. T8.
Figure 4. The comparison between KC, IL-5, and LTB₄ levels in the BALF of the NE group and tiotropium group. A) KC, B) IL-5, C) LTB₄. KC was detected only on Day 8, and the level was significantly lower in the tiotropium group. There were no significant differences in IL-5 levels between the two groups. The LTB₄ level was significantly lower in the tiotropium group on Day 11. Closed bars: NE group. Open bars: Tiotropium group. Data shown are means ± SEM. n = 6-9. * p < 0.05, N11 vs. T11. ** p < 0.001, N8 vs. T8.
Figure 5. The lung sections immunohistochemically stained for M3 receptors on Day 11.
a) NE group, b) Tiotropium group. Strong M3 expression was especially observed in epithelial
cells in the bronchi and inflammatory cells in the NE group. The M3 expression in the
tiotropium group was less than that in the NE group. Scale bar; 200µm.
Figure 6. Therapeutic effect of late administration of tiotropium on established goblet cell metaplasia. A) mucus score, B) total cell count, C) macrophage count, D) eosinophil count.
Comparison between the mucus scores and the results of BALF cell analysis in the NE group and tiotropium group. Tiotropium significantly reduced the mucus score, total cell count, and eosinophil count on Day 20. Closed bars: NE group. Open bars: Tiotropium group. Data shown are means ± SEM. NE group = 12, Tiotropium group = 10. * p < 0.05, N20 vs. T20.

Figure 7. Effect of tiotropium on NE (10⁻⁷ M)-induced MUC5AC production (cell lysate) in NCI-H292 cells. NE increased MUC5AC production in comparison with the control cells. Tiotropium inhibited NE-induced MUC5AC production and significance was obtained at 10⁻⁵ M, but tiotropium (10⁻⁵ M) per se had no effect on baseline MUC5AC production. Ipratropium (10⁻⁵ M) inhibited NE-induced increase in MUC5AC level. Carbachol (10⁻⁶ M) increased the MUC5AC level in NCI-H292 cells, and tiotropium (10⁻⁵ M) inhibited the carbachol-induced increase in MUC5AC level. Data shown are means ± SEM. n = 10 for NE. n = 6 for tiotropium + NE. n = 9 for tiotropium alone. n = 4 for ipratropium +NE. n = 8 for carbachol. n = 7 for
tiotropium + carbachol. Tio, tiotropium. Ipra, ipratropium. Carb, carbachol. † p < 0.05; vs. non-treated control cells. * p < 0.05; vs. NE. # p < 0.05; vs. Carb.